Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary

Aliment Pharmacol Ther. 2023 Jul;58(2):262-263. doi: 10.1111/apt.17610.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Administration, Intravenous
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Hungary

Substances

  • vedolizumab
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents